|
 |
AromasinThis page contains recent news articles, when available, and an overview of Aromasin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Aromasin (when available) aromatase is an enzyme that converts hormones to estrogen in the body's adrenal glands. The aromatase inhibitors (AIs) are drugs that reduce estrogen levels by blocking the action of aromatase in the adrenal glands. The selective AIs (SAIs) selectively reduce levels of estrogen without interfering with levels of other steroid hormones that are produced by the adrenal gland. Drugs in this class include anastrozole (ArimidexÆ), letrozole (FemaraÆ) and exemestane (AromasinÆ). For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. Mechanism Of Action: Breast cancer cell growth may be estrogen-dependent. Aromatase (exemestane) is the principal enzyme that converts androgens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues. Estrogen deprivation through aromatase inhibition is an effective and selective treatment for some postmenopausal patients with hormone-dependent breast cancer. Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing its inactivation, an effect also known as "suicide inhibition". Exemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has no detectable effect on adrenal biosynthesis of corticosteroids or aldosterone. Exemestane has no effect on other enzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibiting the aromatase enzyme. News Articles on Exemestane Tweaks to Breast Cancer Treatments Boost Outcomes - Dec 12, 2009 In the trial, 9775 postmenopausal women with hormone-positive (the most common type) early breast cancer were assigned to get the drug exemestane (Aromasin) ... U.S. News & World Report Pfizer Announces Updated Trial Results For AROMASIN In Switch And Upfront ... - Dec 10, 2009 The company stated that the data showed that women who switched to Aromasin after 2.5 years of tamoxifen experienced a 19% reduction in risk of breast ... RTT News Pfizer updates trial results for Aromasin in switch & upfront settings - Dec 15, 2009 These data showed that women who switched to Aromasin (exemestane tablets) after 2.5 years of tamoxifen experienced a 19 per cent reduction in risk of ... pharmabiz.com Two strategies for breast cancer recurrence may be equal - Dec 23, 2009 ..."This is the only aromatase inhibitor study that has used exemestane as initial endocrine therapy compared to tamoxifen followed by exemestane (Aromasin®)," ... Cancerfacts.com AstraZeneca's Phase III Cancer Drug Faslodex Study Shows Positive Results - Update - Dec 10, 2009 According to the data presented by Pfizer, postmenopausal women who switched to Aromasin after 2.5 years of tamoxifen experienced a 19% reduction in risk of ... RTT News Pfizer reveals updated trial results for Aromasin - Dec 14, 2009 Pfizer this week revealed that its breast cancer treatment Aromasin (exemestane tablets) has been shown to reduce the chances of the recurrence of the ... Zenopa Common Drug May Prevent Bone Loss from Breast Cancer Treatment - Dec 10, 2009 Currently, there are three AI's approved by the US FDA: Anastrazole (Arimedex), exemestane (Aromasin), and letrozole (Femara). Dr. Adam Brufsky, MD PhD, ... eMaxHealth Nexavar to make breast cancer drugs work longer - Dec 12, 2009 ...inhibitors include anastrozole, made by AstraZeneca under the brand name Arimidex, and exemestane, made by Pfizer Inc, under the brand name Aromasin. ... TopNews United States Treatment Updates - Dec 23, 2009 In San Antonio this year, scientists reported whether the women who initially started on the aromatase inhibitor Aromasin (exemestane) did better than the ... Curetoday.com (press release) Pfizer da apoyo integral a pacientes con cáncer - Jan 3, 2010 E. La compañía registra ventas a nivel mundial del orden de 846 millones de dólares con el medicamento Sutent, de 465 millones con Aromasin y de 563 ... Rotativo de Querétaro Nya intressanta data för Aromasin vid adjuvant behandling av bröstcancer - Dec 17, 2009 Nya data för Aromasin (exemestan) visar likvärdig effekt när det gäller sjukdomsfri överlevnad (DFS) och totalöverlevnad (OS) hos kvinnor som behandlats med ... MyNewsdesk (pressmeddelande) Cramer's Mad Money - Agnico Eagle's Golden Disappointment (11/2/09) - Nov 3, 2009 Pfizer has 22 cancer drugs, including Aromasin for breast cancer, Camptoar for colorectal cancer, and its most promising treatment, Stutent, which inhibits ... Seeking Alpha (blog) Jim Cramer Names His Best Picks for Cancer Cures (BMY, IMGN, PFE, DNDN, EXEL) - Nov 9, 2009 Currently, Pfizer has 22 cancer drugs including Aromasin, used for Breast Cancer treatment; Sutent, a drug that limits blood into tumors; and Campotar, ... Benzinga REG-Pfizer Inc Pfizer Reports Third-Quarter 2009 Results - Oct 20, 2009 Examples of products in this business unit include, but are not limited to, Sutent and Aromasin. All revenues for such products are allocated to the ... Reuters A Cure for Cancer? - Nov 4, 2009 Pfizer has 22 cancer drugs, the top performers being Aromasin for breast cancer, Camptoar for colorectal cancer and Sutent, a small molecule drug that ... CNBC Aromasin nel trattamento del tumore al seno a insorgenza precoce - Nov 4, 2009 ...portato allo sviluppo degli inibitori dell'aromatasi di terza generazione, Anastrozolo ( Arimidex ), Letrozolo ( Femara ) ed Exemestane ( Aromasin ). ... XagenaSalute Una rosa podría ayudar a salvar la vida de mujeres dominicanas - Oct 20, 2009 Tiene a disposición de médicos y pacientes Aromasin, que es un inhibidor de aromatasa, comúnmente utilizado en mujeres posmenopáusicas cuyos tumores crecen ... Periódico Primicias Brand Names/Synonyms: Aromasin is also known by the following brand names and/or synonymsAromasin; EXEMESTANE; Exemestance; Exemestane; Exemestane [Inn]; Exemestane [Usan:Inn:Ban]; Exemestano [Inn-Spanish]; Exemestanum [Inn-Latin] Drug Category: Aromasin is categorized under the following by the FDA: Antineoplastic Agents; ATC:L02BG06 Dosage Forms: tablets Absorption: 42% Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 10,13-dimethyl-6-methylidene-7,8,9,10,11,12,13,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
